Navigation Links
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
Date:11/8/2009

MOUNTAIN VIEW, Calif. Nov. 5, 2009 Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays ranged from $8,005 for 87x coverage to $1,726 for 45x coverage for the samples described in this report.

"We've demonstrated that it's possible to accurately and affordably sequence and detect variants across entire human genomes," said Cliff Reid, chairman, president and CEO of Complete Genomics. "This high-quality, cost-effective approach to genome sequencing will allow researchers to study complete genomes from hundreds of patients with a disease to advance the understanding of the genetic causes of that disease, with an end to preventing and treating common human ailments."

The manuscript, titled, "Human Genome Sequencing Using Unchained Base Reads on Self‐assembling DNA Nanoarrays," describes the methodology used to sequence cell lines derived from two individuals previously characterized by the International HapMap project. These included a Caucasian male of European descent (NA07022) and a Yoruban female (NA19240). In addition, researchers sequenced lymphoblast DNA from a Caucasian male sample (NA20431) obtained from the Personal Genome Project (PersonalGenomes.org).

Complete Genomics' proprietary platform enables efficient imaging, while requiring low reagent consumption, through its combinatorial probe anchor ligation (cPAL) chemistry and its use of patterned genomic DNA nanoarrays. With this approach, Complete Genomics' scientists generated high-quality diploid base calls in as much as 95 percent of the genomes sequenced, identifying 3.2 million to 4.5 million sequenc
'/>"/>

Contact: Andrea Long
andreal@waggeneredstrom.com
503-702-8578
Complete Genomics
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
3. Cardium Completes $6.0 Million Registered Direct Offering
4. Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
5. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
6. Stemedica Completes Meeting with the FDA
7. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
8. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
9. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
10. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
11. ePDF is Happy to Announce that ePDF has Completed its First Relaunch, and has Come Out as a Beta
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
(Date:12/13/2014)... 2014 The “Global Synthetic Biology ... drivers, threats, opportunities, and challenges. , The global ... players, namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont ... jointly accounted for approximately ~65% of the total ... Copy for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html ...
(Date:12/13/2014)... York (PRWEB) December 13, 2014 QuickSTAT ... global network and Cold Chain capabilities, and is delighted ... in Paris, France, to serve Life Science clients in ... equipped with a controlled-ambient warehouse, will provide 24/7 transportation ... vaccines and investigational drugs, patient-clinical specimens, API, following IATA ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Glucose Sensors: the Next Generation" ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of ... giving hope for a better future to millions ... can measure glucose levels accurately and reliably have ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... the company has regained compliance with Marketplace Rule,4450(a)(5) (the ... bid,price of the Company,s common stock. Nasdaq had previously ... stock had failed to maintain a,minimum bid price of ...
... 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... Republic of China ("PRC"),today reported solid financial results for ... Fourth Quarter Fiscal 2007 Highlights, -- ... the fourth quarter of 2006, ...
... Verizon Keynote at Leading Pharmaceutical Communication Event, Where Executives Gather to ... for Pharmaceutical, Biotech and Medical Technology ... ... pleased to announce the participation of two keynote speakers from the,U.S. Food ...
Cached Biology Technology:Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 2Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 3Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 4Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 5Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 6Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 7Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 8Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 9FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 2FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 3
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... in Antarctica, funded by the National Science Foundation (NSF), have ... and greenhouse gases in the atmosphere that extends back 68,000 ... the ice containing the record is known as the WAIS ... the core contain uniquely detailed information on past environmental conditions ...
... molds and fungi, bacteria and viruses. To kill them off ... are, as a rule, treated chemically. However, recently this method ... have been withdrawn, but the granting of new permits has ... E. coli infection which was caused by beansprout ...
... ARBORMany medically minded researchers are in hot pursuit of ... and the interiors of cells, but University of Michigan ... to overcome: escaping the bloodstream. Drug delivery ... medicines could be more effective at lower doses and ...
Cached Biology News:Antarctic ice core contains unrivaled detail of past climate 2Antarctic ice core contains unrivaled detail of past climate 3Healthy seeds -- treated environmentally friendly 2Healthy seeds -- treated environmentally friendly 3Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 2Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Glutathione Agarose Beads 10 ml...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: